Alterity Therapeutics Ltd 6-K, filed Jul 15, 2024
Alterity Therapeutics Ltd (ATHE)
About this 6-K
Alterity Therapeutics Ltd filed this 6-K on July 15, 2024.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2024
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
| 99.1 | Trading Halt |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | ||
| By: | /s/ Geoffrey P. Kempler | |
| Geoffrey P. Kempler | ||
| Chairman | ||
Date: July 14, 2024
2
Exhibit 99.1
Market Announcement
15 July 2024
Alterity Therapeutics Limited (ASX: ATH) – Trading Halt
Description
The securities of Alterity Therapeutics Limited (‘ATH’) will be placed in trading halt at the request of ATH, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 17 July 2024 or when the announcement is released to the market.
Issued by
ASX Compliance
| 15 July 2024 | Market Announcement 1/1 |
| ASX Limited | ASX Customer Service Centre 131 279 | asx.com.au |
15 July 2024
Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 50, South Tower, Rialto 525 Collins St
Melbourne VIC 3000
| By email: | TradingHaltsMelbourne@asx.com.au |
| ListingsComplianceMelbourne@asx.com.au |
Dear Melissa
Request for a trading halt – Alterity Therapeutics Limited
In accordance with ASX Listing Rule 17.1, Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (the Company) requests that its securities be placed into an immediate trading halt pending an announcement in relation to new data from an ATH434 clinical trial.
The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Wednesday, 17 July 2024, whichever is the earlier.
The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.
Please contact me if you require any further information.
Yours sincerely
Phillip Hains
Company Secretary
Alterity Therapeutics Limited ABN 37 080 699 065
Level 14, 350 Collins Street, Melbourne, VIC 3000 Australia
T: +61 (0)3 9349 4906 | www.alteritytherapeutics.com